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Abstract Focal dystonia is a common, invalidating neu-
rologic condition characterized by involuntary, sustained
muscle contractions causing twisting movements and
abnormal postures in one body part. Currently, botulinum
toxin is the treatment of first choice. We performed a
systematic review towards the pharmaco-therapeutic and
pharmaco-economic value of botulinum toxin as treatment
for focal dystonia, which yielded the following results.
Botulinum toxin is the most effective treatment for
reducing dystonic symptoms measured with dystonia-spe-
cific and general questionnaires, and pain in patients with
focal dystonia. Seventy-one percent of patients with cer-
vical dystonia had a reduction in neck pain compared to
12 % in placebo groups. Adverse events occur in 58 % of
patients during treatment with botulinum toxin compared
to 46 % treated with placebo. Especially dry mouth, neck
weakness, dysphagia, and voice changes are common.
Adverse events are usually mild and self-limiting. Health-
related quality of life, measured with the SF-36 is 20–50
points lower in patients with focal dystonia compared to
controls and the effect of botulinum toxin on health-related
quality of life is unclear. Botulinum toxin treatment is
expensive because the drug itself is expensive. Yearly costs
for treating a patient with focal dystonia with botulinum
toxin range from EUR 347 to EUR 3,633 and the gain in
QALYs with BTX treatment is small. Focal dystonia
impairs the productivity and the ability to work. At start of
botulinum toxin treatment only 47–50 % was working.
Botulinum toxin partly improves this. Overall, we conclude
that botulinum toxin is an expensive drug with good
effects. From a societal perspective, the costs may well
weigh up to the regained quality of life. However, the
available literature concerning costs, health-related quality
of life and labor participation is very limited. An extensive
cost-effectiveness study should be performed incorporating
all these aspects.
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Introduction
Dystonia is a syndrome characterized by involuntary, sus-
tained muscle contractions causing twisting movements
and abnormal postures [32]. Dystonia is the third most
common movement disorder (annual incidence: 15–25 per
100,000) [11, 19] after Parkinson’s disease [36] and tremor
[20]. Dystonia can be classified based on topographic dis-
tribution, including focal dystonia (one body region), seg-
mental dystonia (two or more adjacent regions), multifocal
dystonia (two or more nonadjacent regions), hemidystonia
(ipsilateral arm and leg) and generalized dystonia [32].
Focal dystonia (FD) is the most common form of dystonia
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and can occur in every body part. Most often focal dystonia
occurs in the neck (cervical dystonia, CD), but it can also
occur in the eyelids (blepharospasm, BPS) or hands (task-
specific or focal hand dystonia) [32]. The treatment of first
choice is botulinum toxin (BTX), a neurotoxin that blocks
the neuromuscular signal transmission [32]. In this sys-
tematic review, we assess the pharmaco-therapeutic value
of botulinum toxin as treatment for FD including health-
related quality of life. In addition, a systematic review of
the pharmaco-economic value is performed.
Methods
Relevant systematic reviews, randomized controlled trials
(RCTs), and observational studies were identified by sys-
tematic searches in the Cochrane database, the Database of
Abstracts of Reviews of Effects (DARE), Medline (from
year of publication 1966 until November 2011), and Em-
base (from year of publication 1980 until November 2011).
Language was limited to Dutch, English, German, and
French. Articles concerning animal studies were excluded.
Economical studies were sought in the economic evalua-
tions of the Cochrane library, Medline, Embase and the
NHS Economic Evaluation Database (NHS EED). Search
terms that we used were a combination of ‘‘focal dystonia’’,
‘‘cervical dystonia’’, ‘‘blepharospasm’’, ‘‘writer’s cramp’’,
‘‘hand dystonia’’, ‘‘oromandibular dystonia’’ or ‘‘Meige’s
syndrome’’ and ‘‘botulinum toxin’’, ‘‘botulinum toxin A’’,
‘‘botulinum toxin B’’, ‘‘Dysport’’, ‘‘Botox’’ or ‘‘Xeomin’’.
We searched for relevant systematic reviews first. Identi-
fied reviews were assessed for their methodological quality
by two reviewers (JMD and INVS) using a standardized
Dutch form that was developed by the Dutch Institute for
Healthcare Improvement (CBO) and the Dutch Cochrane
Centre [1]. In case the two reviewers disagreed on the
quality of the articles, articles were discussed with the
other authors until consensus was reached. Reviews that
were assessed as good were used, and than additional case-
cohort and observational studies were not included. If a
review did not cover all the available literature, additional
RCTs were sought from the end date of the literature search
of the most recent review and assessed for their quality. In
case there were no good reviews or RCTs, case-cohort or
observational studies were sought and used. The available
literature differs substantially for several relevant aspects
of botulinum toxin treatment. Therefore, the best available
literature was sought for each of these relevant topics. The
topics discussed in this review are: favorable effects,
adverse events, health-related quality of life, costs, and
labor and/or production loss. Because of the available
literature, the search results were divided into two parts: a
therapeutic part (favorable effects and adverse events; most
available literature) and an economical part (quality of life,
costs and labor participation; less available literature). The
results of the searches are depicted in two flow-charts, see
flow-chart 1 and flow-chart 2. Main reasons to exclude
articles or to not assess articles at full-text were: double
search results, the article concerned another disorder, the
article concerned another treatment, diagnostics or inter-
vention or mentioning of the topics at interest (e.g., adverse
events, costs or quality of life) only in the discussion part
of the abstract. At the end of the article, we added an
evidence paragraph stating the used articles and their evi-
dence level per subheading.
To allow an adequate comparison of the costs reported
in different cost-effectiveness studies, we adapted the costs
to the Dutch situation according to the existing interna-
tional guideline for good research practices for measuring
drug costs [25]. Costs were adapted to Dutch euros in the
year 2009. We used consumer price index values for the
local currency to derive the cost equivalents for 2009
(Institut National de la Statistique et des e´tudes e´conomi-
ques, http://www.bdm.insee.fr; Statistisches Bundesamt
Deutschland, http://www.destatis.de; Office for National
Statistics, http://www.statistics.gov.uk; all accessed late
December 2010). Cost estimates based on local currencies
from before the introduction of the euro in 2001 were
converted into euro. Subsequently, purchasing power par-
ities for actual individual consumption (Organisation for
Economic Cooperation and Development; stats.oecd.org)
were used to convert the price-indexed estimates to ‘Dutch’
euros.
What are the favorable effects of BTX treatment?
Favorable effects of BTX have been measured in several
ways in different studies. Three frequently used outcome
measures in studies were relief of dystonic symptoms,
(self)-reported improvement of symptoms, and pain relief.
Dystonic symptoms
Patients with FD improved significantly with BTX treat-
ment when symptoms were measured with dystonia-spe-
cific scoring instruments [30, 33, 34, 37]. In the identified
studies, the Tsui scale and Toronto Western Spasmodic
Torticollis Rating scale (TWSTRS) were used for CD [30]
and the blepharospasm rating scale [BRS; also referred to
as the Jankovic Blepharospasm Rating scale (JBRS)], the
Blepharospasm Disability scale (BDS) and the Blepharo-
spasm Disability Index (BSDI) were used for BPS [34, 37].
Improvement was detected for changes in the mean scores
on the Tsui and TWSTRS for CD, the JBRS, BDS, and
BSDI for BPS and sound spectrograms for spasmodic
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dysphonia (dystonia of the vocal cords), but also for the
proportion of patients with a clinically relevant difference
on these scales (e.g., C3 points improvement on the Tsui
scale or C20 % improvement on the TWSTRS).
Improvement on the above named scales has been shown in
studies using BTX type A and B in patients with different
forms of FD [30, 33, 34, 37]. Several studies demonstrated
that the effectiveness of BTX type A on the relief of dys-
tonic symptoms in patients with CD showed no significant
difference compared to type B [30]. The effect of BTX on
dystonic symptoms lasted at least 12–16 weeks in both
patients with CD and in patients with BPS consistent with
the 12 week treatment interval used in clinical practice for
both treatment groups [30, 34, 37]. Trihexyphenidyl, an
anticholinergic drug, is the most commonly used drug,
besides BTX, for the treatment of FD. This drug has been
compared to BTX type A in patients with CD. The effect
was measured using the Tsui and the TWSTRS. Trihexy-
phenidyl was significantly less effective compared to BTX
in improving symptoms on these scales [3].
In a large review, no systematic reviews or RCTs
evaluating other drugs for the treatment of focal dystonia,
such as antipsychotics, dopamine (ant-)agonists or seroto-
nin (ant-)agonists were identified [30].
(Self-)reported improvement
Positive effects have also been shown on more general
questionnaires measuring improvement of symptoms
according to the patient or physician (e.g., Patient global
assessment of change) in patients with CD and BPS in studies
comparing BTX type A and B to placebo [3, 30]. Physicians
reported a beneficial effect on symptoms of dystonia in
37–65 % of patients with CD (depending on dose) and
94–97 % of patients with BPS treated with BTX compared to
17–30 % in the various placebo groups [30, 34]. Patients
with CD considered BTX treatment beneficial in 43–68 %
(depending on dose) compared to 10–22 % of the placebo
group [30]. In BPS, 87–97 % of patients in the BTX group
reported a beneficial effect, compared to 25 % of patients in
the placebo group [34]. In the only methodologically good
RCT in patients with writer’s cramp that was identified in a
large review [30] 70 % of patients in the BTX group
expressed the wish to continue treatment compared to 32 %
of patients in the placebo group [18]. Different dosages of
both BTX type A and B have been compared to placebo in
patients with CD. The proportion of patients that reported
improvement was larger when higher dosages were used.
Physicians also reported improvement in a larger proportion
of patients when higher dosages of BTX were used. This
came at the cost of more adverse events (see ‘‘Adverse
events’’). Unfortunately, no direct comparisons have been
made between the low- and high-dose groups [30, 34].
Pain
Pain is an important problem in patients with CD but not in
patients with other forms of FD [32]. Seventy-five percent
of CD patients suffer from invalidating neck pain [32].
Treatment with both BTX type A and B significantly
reduced neck pain: 71 % of patients treated with BTX had
a reduction in neck pain versus 12 % of patients treated
with placebo [30]. BTX was more effective than trihexy-
phenidyl in reducing neck pain: 2–3 points improvement
on TWSTRS-pain in the BTX group versus 1 point in the
placebo group [3].
What are the adverse events of BTX treatment?
Adverse events are common in BTX trials in patients with
FD. In the identified articles, they were only reported in
patients with CD and WC, but they may occur in all forms
of FD. In a large review, 58 % of patients with CD treated
with BTX type A experienced adverse events compared to
46 % treated with placebo [30]. The most common adverse
event was dry mouth in 19–41 % of patients treated with
BTX type A and 22–80 % of patients treated with BTX type
B [30]. Other common adverse events were neck weakness
(18 %), dysphagia (3.4–19.4 %) and voice change or
hoarseness (7 %) [8, 30]. Incidence of adverse events
increased with increasing dosages, both for BTX type A and
B. Most adverse events were mild and self-limiting [30].
One of the most feared possible adverse events of BTX
treatment is systemic weakness. According to a recent lit-
erature review, this mainly occurred in patients treated with
injections exceeding 600 units of Botox (e.g., spastic par-
aparesis). Only one case of systemic weakness in a patient
with CD has been reported in the literature. This female
patient received 650 U of Dysport and developed fatigue,
limb weakness, and dysphagia after 1 week. The complaints
lasted for 6 months [9]. Death, although warned for by the
FDA, is an extremely rare side-effect and was not men-
tioned in any of the identified studies, nor did we identify
any case reports of fatalities in patients with dystonia.
In CD patients treated with trihexyphenidyl, adverse
events are more common compared to BTX treated CD
patients [3].
In 40 patients with WC weakness in the hand was more
common in the BTX group (18/20; 90 %) than in the
placebo group (2/19; 11 %), although there was no p value
reported. Pain at the injection site also was a common
adverse event in these patients, but rates were comparable
between the BTX group (1/20; 5 %) and placebo group
(3/19; 16 %) [18].
Another unfavorable event associated with BTX treat-
ment is the possibility of antibody formation due to the
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injection of a foreign protein. In a large series, 17 of 303
patients became secondary non-responders. Nine of those
17 (3 % of total) had detectable antibodies [29]. Primary
failure to BTX because of resistance is very rare [29].
How is the quality of life of patients with focal dystonia?
Quality of life is measured with and quantified by general
(e.g., SF-36 or EQ5D) or disease-specific quality of life
questionnaires and is therefore different from self-reported
well-being. Scores on quality of life questionnaires can be
used to compare the disease burden of different conditions.
Furthermore, gain in quality of life can be weighed against
treatment costs [14].
Health-related quality of life of patients with FD was
significantly worse compared to the general population in
all identified studies [2, 6, 12, 15, 16, 23, 24, 26, 28, 31,
35]. In most studies, health-related quality of life was
measured with the SF-36, a questionnaire consisting of 36
items that can be divided into eight domains. Both total and
domain scores can range from 0 to 100 [38]. Patients with
FD scored 20–50 points lower on the total score compared
to the general population [2, 6, 12, 16, 23, 26, 28]. Scores
were comparable to patients with multiple sclerosis, Par-
kinson’s disease or stroke [6, 24]. Scores were lower on all
SF-36 domains [12, 16, 23, 26, 28]. Patients with CD
scored worse on the bodily pain domain compared to
patients with other forms of FD [16, 23, 24]. A study in
patients with spasmodic dysphonia found no differences in
SF-36 scores between patients and normative scores for the
general population, but, using a more disease-specific
voice-related quality of life questionnaire (V-RQOL),
quality of life was markedly reduced in patients [31].
The most important determinants of worse health-rela-
ted quality of life were depression and anxiety [2, 15, 24,
26, 28]. In one study, 47 % of patients with BPS and CD
fulfilled the criteria for depression [23]. Predictors for
lower health-related quality of life were more severe dys-
tonia [2, 23, 26], longer disease duration [2], pain [23, 24],
higher age [26], female gender [6, 23], low self-deprecation
[2], being single [2] and being unemployed [12, 24]. On the
other hand, longer disease duration [23, 31] and higher age
[12] were also associated with better health-related quality
of life.
The effect of BTX on health-related quality of life is
unclear and studies differ on this point. This is partly due to
short follow-up: 4 weeks follow-up in two studies [23, 28],
12 weeks in one study [16], and 6 months in one study
[12]. For BTX treatment, this is still relatively short, since
one treatment cycle is 3 months. One study in patients with
CD showed a significant improvement on all SF-36
domains after BTX treatment, for some domains even to
the level of the general population [28]. In another study
there was only a mild improvement in SF-36 domain scores
in patients with CD. The health-related quality of life of
patients with BPS did not improve with BTX treatment
[23]. Two studies showed a mild improvement in SF-36
scores in patients with all types of dystonia when BTX was
working (after *4 weeks) and a decline when the effect
wore off (after *12 weeks) [12, 16]. These changes were
statistically significant in only one of those studies in
patients with CD and BLS [16].
One study reported score distribution of the different
EQ5D dimensions in patients with focal dystonia, com-
pared both to patients with non-focal dystonia and the
general population. They included 93 patients with differ-
ent forms of focal dystonia, of which 81 patients were
being treated with BTX. Overall, patients with focal dys-
tonia scored significantly worse on all five dimensions
compared to the general population. The overall utility
index improved after BTX treatment and worsened again
as treatment effects wore off [12].
What are the costs of BTX treatment?
Yearly costs of botulinum toxin treatment for FD ranged
from EUR 347 to EUR 3,633, depending on number of
treatment sessions per year and type of dystonia treated [4,
5, 7, 10, 13]. The lowest costs were for treating BPS
patients three times a year and the highest for treating CD
patients five times a year [5, 10]. Yearly costs for not
treating FD patients were estimated to be between EUR
248 and EUR 1,014 and consisted of visits to the outpatient
clinic, other medication and physiotherapy, among others
[4, 13]. Most studies only incorporated direct medical costs
that mainly consist of the costs of the toxin itself. A recent
study looked more extensively at the costs of treating
patients with neurological conditions, including focal
dystonia, with BTX. The authors included costs of the
toxin (EUR 154.36 for 100 IU Botox and EUR 215 for
500 IU Dysport), salaries of the treating physician, assist-
ing nurse and secretary, needles, EMG equipment and
social costs (transportation by taxi with an accompanying
person). They estimated that the daily costs were EUR
1.30 ± 0.30 for treating a BLS patient, EUR 1.52 ± 0.73
for a patient with oromandibular dystonia, EUR
3.28 ± 0.86 for CD and EUR 1.15 ± 0.35 for occupational
dystonia (not further specified). This leads to yearly costs
ranging from EUR 419.75 for occupational dystonia to
EUR 1,197.20 for cervical dystonia. Subjective improve-
ment in these patients varied between 2.2 and 2.4 on a four-
point rating scale [5].
In cost-effectiveness studies, benefits are usually mea-
sured in gained quality adjusted life years (QALYs). The
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range of yearly gain in QALYs following BTX treatment was
0.015–0.114, depending on the type of valuation (time trade-
off or visual analogue scale) and type of focal dystonia [7,
13]. Saved costs for remaining at work (direct non-medical
costs) and not buying over the counter drugs (indirect non-
medical costs) were not assessed. Extra costs per gained
QALY ranged from EUR 5,301 to EUR 94,770, depending
on the baseline health-related quality of life, the valuation
methods of health status applied (visual analogue scoring
versus time trade-off based elicitation of preferences),
treatment costs and type of FD, suggesting that health care
efficiency may substantially differ between patient groups.
This could indicate that limits for treatment indications must
be set in the future [7, 13]. Based on the type of patients
treated, average BTX dose, dosing interval and average gain
in QALYs, an estimate of EUR 40,000 per gained QALY is
probably most realistic for the Dutch situation.
All studies mentioned that the costs of BTX treatment
for FD mainly consist of the costs of the toxin itself, since
BTX is an expensive drug [4, 5, 7, 10, 13, 40]. Other cost
drivers include for example material, personnel costs, and
travel expenses [5]. One study evaluated whether the costs
could be lowered by getting an outreach nurse practitioner
to administer the BTX at the patient’s home. This was at
least as effective and safe as treatment at the outpatient
clinic, and was valued significantly higher by patients. The
costs of the visit (excl the BTX) were halved, but the
difference on total costs was not significant, since BTX was
the main cost driver [40].
How do focal dystonia and BTX treatment influence
labor participation?
Indirect costs that originate when patients are not able to
work have not been evaluated in any of the above-named
studies. Therefore, we looked for articles discussing the
effect of FD and BTX treatment on work. We identified
three Scandinavian studies in patients with CD.
Before the first symptoms of dystonia became apparent,
78.7–84 % of patients were working [22, 27]. This per-
centage had dropped to 47–50 % at the start of BTX
treatment and was 52 % after long-term BTX treatment
[21, 22, 27]. Of the patients at work at the start of BTX
treatment, 72 % remained employed. Of the patients on
sick leave at the start, 67 % returned to work [27]. Fifty-
three percent of patients reported a negative effect of CD
on work and 68.9 % reported a negative effect on pro-
ductivity [22]. In total, 18.9–47 % had to quit working or
retire early because of dystonia [21, 22]. This effect was
already noticeable at the age of 40 years. At the age of
50 years, only 25 % of patients were working compared to
62 % of the general population [21].
In CD patients, BTX had a better effect on work and
productivity compared to oral medication. Also, the
adverse effects of BTX had a smaller effect on work and
productivity [22]. Important predictors of staying at work
were younger age (\55 years) and longer education [27]. A
predictor of being unemployed was neck pain [22].
Discussion
The favorable effects of BTX treatment for patients with
FD have been well described and are well known, as are
the possible adverse events. BTX is the first treatment of
choice when treating patients with different forms of FD.
This is partly due to the favorable effects of BTX, but also
because it is the best-studied treatment option in these
patients. Over the last years, deep brain stimulation (DBS)
has been an upcoming treatment for different forms of
dystonia. We chose not to incorporate studies investigating
DBS as a possible treatment for FD, since thus far DBS is
used in a selected patient group where BTX treatment has
failed. Furthermore, DBS as treatment for dystonia could
be and has been a review subject itself [17, 39, 41].
The other topics we discuss (quality of life, costs, and
labor participation) have been less well studied in patients
with focal dystonia who are treated with BTX. To our
knowledge, this is the first review gathering the available
literature on these topics. The impact of FD on health-
related quality of life appears to be large, but has, to our
knowledge, never been reviewed before. Gathering the
available evidence improves comparison of the disease
burden of patients with FD to patients with other condi-
tions. Studies evaluating the effect of focal dystonia on
labor have only been performed in Scandinavian countries.
These countries differ in their pension system and health-
care system from, for example, the Netherlands making it
difficult to compare the data to the Dutch situation. The
costs of BTX treatment for focal dystonia have not been
reviewed before. Unfortunately, all studies include differ-
ent cost components (see Table 1). Thus far, there has not
been a cost-effectiveness study that incorporated all med-
ical and non-medical costs. In the most complete and most
recent cost study, QALYs were not evaluated, making it
difficult to assess cost-effectiveness [5]. Based on data
from the other studies, we estimated costs/QALY to be
approximately EUR 40,000 for treating an FD patient with
BTX, making BTX an expensive treatment. Indirect costs
of lost production due to work absenteeism could not be
retrieved from the reported studies, however, data on labor
participation show that at least one-third of the patients
stop working when the disease progresses, while being at
work does not guarantee full productivity. Compared to
oral medication, however, BTX seemed to exert a
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favorable influence on labor participation. From a societal
perspective, however, the costs may well weigh up to the
regained quality of life, making the drug affordable.
The study has some limitations. First, as stated above, the
information on health-related quality of life, treatment costs
and labor participation in patients with focal dystonia is
limited. This makes it difficult to draw any hard conclusions
from the available literature. Second, most studies we
included concern patients with cervical dystonia, the most
common, and thus the most studied form of focal dystonia
[32]. Even favorable effects and adverse events have not
been well studied in other forms of focal dystonia. Third
and last, it is always possible that we missed relevant ref-
erences. We performed an extensive literature search, so we
think it is unlikely we missed important references during
our search. However, when available, we included reviews
of sufficient quality and did not search for missing RCTs in
the period covered by the review. We can not exclude that
the reviews we included missed relevant references.
Concluding, BTX is the first treatment of choice for
focal dystonia. BTX has large favorable effects and little
adverse events. Available literature on the topics of health-
related quality of life, costs, and labor participation is
limited, but it appears that BTX is an expensive treatment
that can improve quality of life and labor participation. A
cost-effectiveness study that incorporates all direct and
indirect medical and non-medical costs should be per-
formed. In our opinion, the next step would be an inter-
national study evaluating all possible costs of BTX
treatment including labor participation and quality of life.
This study should include patients with different forms of
focal dystonia. Since BTX is considered the first treatment
of choice in most forms of focal dystonia, it would be
unethical to perform a placebo-controlled trial, but new
patients could be compared before and after BTX
treatment.
Evidence
Below is a summary of the evidence class of the articles we
based this article on. Evidence is summarized per sub-
heading. The articles represent the best available evidence.
Favorable effects
One review covering literature up to February 2011 (class
I) [30] and one additional RCT (class I) [37]. In the review,
some subjects were covered by only one RCT, in that case
the original study was used. The three studies concerned
were all RCTs (class I) [3, 18, 33]. We identified one other
RCT that was not mentioned in the review and that was of
sufficient quality according to our method, so we incor-
porated this RCT as well [34].
Adverse events
Four reviews (class I) [8, 9, 29, 30] covering the available
literature up to February 2011 and one RCT (class I) [3]
extracted from one of the reviews (see above).
Quality of life
Four studies with a before-and-after design (class III) [12,
16, 23, 28] and seven cross-sectional studies (class IV) [2,
6, 15, 24, 26, 31, 35].
Costs
Four cohort studies (class III) [4, 5, 10, 40] and two cross-
sectional studies (class IV) [7, 13].
Labor
Three cross-sectional studies (class IV) [21, 22, 27].




Burbaud Chadda Dodel Gudex Whitaker
BTX 9 9 9 9 9 9
Clinic-related costs (e.g., outpatient visits) 9 9 9 9 9
Transportation and/or traveling costs 9 9 9
Needles and/or EMG equipment 9 9
Salaries of medical personnel 9 9
Other medication 9 9
Salaries of non-medical personnel 9
Physiotherapy 9
Diagnostic costs 9
Patient lost time from work 9
Escort lost time from work 9
Administration 9
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